Important win in Norway (NOK 192m)
NetCompany has today won an important contract in Norway.
Legemiddelverket (the Norwegian Medicines Agency) has awarded
Netcompany a NOK 192m order for the development contract for a new IT
platform. This is the company’s ﬁrst large contract in Norway, and is a
landmark for the company. The order will improve utilisation from “today”
in the Norwegian business and, once in operation, work as a reference
client in the country. After several tenders where NetCompany apparently
ended up #2 or #3, we consider this an important win. We maintain our
combined DCF- and peer group-based valuation range of DKK 450-525 per
share and leave our estimates unchanged.
Generalt om Commissioned Research: Bemærk, at man bør se bort fra eventuelle kursestimater i såkaldt commissioned research, og den underliggende analyse skal også tolkes med forsigtighed, da negative aspekter ikke nødvendigvis fremhæves.